Saturday, April 30, 2022 4:40:21 PM
MMND and CMPS are both doing Trials for the mental health uses of psychedelics. CMPS's recent trial was single large dose. I personally wouldn't support that level of a 'high' for anyone and like another company's MOU much better.
They both had larger MCs but are still about $300-400M now. Both have $0 revs.
AGN has followed the different path of the neuroplasticity effects of micro dosed DMT.
Seems a Big difference in the MOUs / applications of psychedelics with different patient groups.
Dr Nutt has significant insights for Both, IMO.
An occasional small dose of Shrooms DOES mitigate some of the side effects of chemo and mental stress, IMO. True hallucinogenic experiences should be left to the young and dumb, IMO...GLTA...
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM